Compare NLY & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NLY | HOLX |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Electronics |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 16.6B |
| IPO Year | 1997 | 1990 |
| Metric | NLY | HOLX |
|---|---|---|
| Price | $22.86 | $74.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 15 |
| Target Price | $21.63 | ★ $79.64 |
| AVG Volume (30 Days) | ★ 6.7M | 3.0M |
| Earning Date | 10-22-2025 | 11-03-2025 |
| Dividend Yield | ★ 12.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.19 | ★ 2.49 |
| Revenue | $1,748,174,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $358.71 | $6.69 |
| Revenue Next Year | $8.02 | $5.74 |
| P/E Ratio | ★ $10.42 | $30.11 |
| Revenue Growth | ★ 275.23 | 1.74 |
| 52 Week Low | $16.60 | $51.90 |
| 52 Week High | $22.98 | $80.31 |
| Indicator | NLY | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 70.52 | 67.93 |
| Support Level | $22.66 | $74.55 |
| Resistance Level | $22.98 | $75.12 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 92.11 | 78.92 |
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.